Abstract

This is an in-depth discussion about the regulatory situation of psychedelic substances in European and North American health systems. The program will evolve around study requirements, HTA, reimbursement in private and public health systems, special and early access programs, and the link between psychedelic substance application to psychotherapy. We will also cover potential regulatory differences between North America, UK, Australia and Europe.